SPONSOR

Fudan University

Total Trials

Recruiting

Phases

Phase 3, Phase 1, Phase 2, Phase 4, Phase 2, Phase 2, Phase 3, EARLY_Phase 1

Conditions studied: Breast Cancer Adjuvant Therapy High-Risk Localized Soft Tissue Sarcoma Type 2 Diabetes Mellitus Cognitive Impairment Colorectal Cancer Relapse Opioid-free Anesthesia NETs Carcinoma, Non-Small-Cell Lung

Fudan University is a clinical research sponsor with 51 registered studies on ClinicalTrials.gov, of which 51 are actively recruiting participants. Research covers conditions including Breast Cancer, Adjuvant Therapy, High-Risk Localized Soft Tissue Sarcoma, Type 2 Diabetes Mellitus.

The trial portfolio spans Phase 3, Phase 1, Phase 2, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Fudan University

How many clinical trials has Fudan University sponsored?

ClinicalMetric currently tracks 51 clinical trials sponsored by Fudan University, of which 51 are actively recruiting participants. These trials cover conditions including Breast Cancer, Adjuvant Therapy, High-Risk Localized Soft Tissue Sarcoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Fudan University research focus on?

Fudan University clinical trials span Breast Cancer, Adjuvant Therapy, High-Risk Localized Soft Tissue Sarcoma, Type 2 Diabetes Mellitus, Cognitive Impairment, and additional conditions. The research pipeline includes Phase 3, Phase 1, Phase 2, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Fudan University clinical trial?

To participate in a Fudan University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fudan University trials with current recruitment status updated daily.

Fudan University

Frequently Asked Questions — Fudan University

Clinical Trials by Fudan University

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma

Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment

A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy

Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery

ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer

Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases

Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC

Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer

Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma

Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer

Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer

Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal Metastases

Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery

Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer

PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency

The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

Olive Oil Before Lung Cancer Surgery to Prevent Chylothorax

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase

Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

Laparoscopic vs Open Total Gastrectomy for Gastric Cancer

Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)

Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

Postoperative Effects of Different Enterostomy Approaches

Adjuvant Radiotherapy in High Risk Locally Advanced DTC

A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases